← Back to Search

Device

Active for Epilepsy (eTNS for DRE Trial)

N/A
Waitlist Available
Research Sponsored by NeuroSigma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18-65
Partial onset seizures (complex partial or secondary generalized tonic-clonic)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up four weeks
Awards & highlights

eTNS for DRE Trial Summary

The purpose of this study is to evaluate the tolerability and safety of the NeuroSigma eTNS system.

Eligible Conditions
  • Epilepsy

eTNS for DRE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

eTNS for DRE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~four weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and four weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety of eTNS
Secondary outcome measures
Beck Depression Inventory
Quality of Life
Skin Irritation
+1 more

eTNS for DRE Trial Design

1Treatment groups
Experimental Treatment
Group I: ActiveExperimental Treatment1 Intervention
Trigeminal nerve stimulation

Find a Location

Who is running the clinical trial?

NeuroSigma, Inc.Lead Sponsor
1 Previous Clinical Trials
25 Total Patients Enrolled
Olive View-UCLA Education & Research InstituteOTHER
33 Previous Clinical Trials
879,994 Total Patients Enrolled
2 Trials studying Epilepsy
200 Patients Enrolled for Epilepsy

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~2 spots leftby Mar 2025